If You Invested in Dbv Technologies S A (DBVT)

DBV Technologies S.A. (NASDAQ: DBVT; Euronext Paris: DBV) is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. According to the company’s disclosures, DBV Technologies is focused on investigating the use of its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) to address food allergies, which are caused by a hypersensitive immune reaction and can lead to symptoms ranging from mild discomfort to life-threatening anaphylaxis. The company is headquartered in Châtillon, France, and has North American operations in Warren, New Jersey.

DBV Technologies’ core technology platform is Viaskin, a skin patch designed to deliver microgram amounts of a biologically active compound to the immune system through intact skin. The therapeutic approach, called epicutaneous immunotherapy (EPIT), is described by the company as a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to an allergen. EPIT leverages the skin’s immune tolerizing properties to promote desensitization while avoiding direct injection or ingestion of the allergen.

Focus on food allergy treatments

DBV Technologies states that millions of people live with food allergies, including young children, and that current options are limited, often relying on strict avoidance and emergency management of reactions. The company is developing product candidates that aim to offer new treatment options for these patients. Its food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut-allergic toddlers aged 1 through 3 years and children aged 4 through 7 years.

The company has highlighted Viaskin Peanut as its main product candidate. In company communications, Viaskin Peanut is being evaluated as a potential treatment for peanut-allergic children using the Viaskin patch platform. DBV Technologies reports that its pivotal Phase 3 VITESSE trial of the Viaskin Peanut patch in peanut-allergic children aged 4 to 7 years met its primary endpoint, and that safety results were consistent with the safety profile observed in the Viaskin Peanut clinical program to date. The company has also described VITESSE as a large, randomized, double-blind, placebo-controlled study in this patient population.

Epicutaneous immunotherapy (EPIT) approach

DBV Technologies explains that through EPIT, the Viaskin patch is designed to introduce very small quantities of allergen or other biologically active compounds to the immune system via intact skin. The goal is to gradually desensitize the immune system to the allergen over time. The company characterizes EPIT as non-invasive and focused on modifying the underlying allergy rather than only treating acute reactions. This approach is central to DBV Technologies’ strategy for food allergy and other immunologic conditions.

Pipeline and clinical programs

In its public materials, DBV Technologies describes itself as a clinical-stage or late-stage biopharmaceutical company. Its food allergy programs include:

• Ongoing clinical trials of Viaskin Peanut in peanut-allergic toddlers (1 through 3 years of age).
• Ongoing clinical trials of Viaskin Peanut in peanut-allergic children (4 through 7 years of age), including the Phase 3 VITESSE trial.

The company has also referred to a supplemental safety study (COMFORT Toddlers) in peanut-allergic toddlers aged 1 to 3 years, indicating continued clinical investigation in this younger age group. Earlier descriptions of DBV Technologies’ activities reference additional food allergy programs, such as Viaskin Milk and work related to eosinophilic esophagitis, but the company’s most recent communications emphasize Viaskin Peanut and its associated clinical trials.

Stock listings and corporate structure

DBV Technologies’ ordinary shares trade on segment B of Euronext Paris under the ticker symbol DBV, with ISIN code FR0010417345. The company’s American Depositary Shares (ADSs), each representing five ordinary shares, trade on the Nasdaq Capital Market under the symbol DBVT (CUSIP: 23306J309). The company has also reported information on its total number of shares and voting rights in accordance with the regulations of the Autorité des Marchés Financiers in France.

Through its dual listing on Euronext Paris and Nasdaq, DBV Technologies provides access to both European and U.S. investors. The company has used equity financing tools, including warrants and at-the-market offerings of ADSs, as described in its regulatory filings, to support its clinical development and corporate activities.

Regulatory and clinical milestones

DBV Technologies has reported several notable regulatory and clinical developments related to Viaskin Peanut. The company has stated that the U.S. Food and Drug Administration (FDA) previously granted Breakthrough Therapy Designation for the Viaskin Peanut patch. It has also indicated its intention to submit a Biologics License Application (BLA) in the United States for Viaskin Peanut in children aged 4 to 7 years, followed by a planned submission for toddlers aged 1 to 3 years, aligning these plans with the positive topline results from the VITESSE Phase 3 trial.

In addition to clinical and regulatory updates, DBV Technologies periodically reports financial results, business highlights, and corporate governance changes, such as appointments and resignations of directors and senior executives, through press releases and SEC filings.

Geographic footprint

DBV Technologies is based in Châtillon, France, and notes that it maintains North American operations in Warren, New Jersey. Its clinical trials, including the VITESSE Phase 3 study, have involved sites in the United States, Canada, the United Kingdom, Europe, and Australia, reflecting a global clinical development footprint as described in company communications.

Summary

According to its public statements, DBV Technologies S.A. is focused on developing non-invasive, EPIT-based treatments for food allergies, with Viaskin Peanut as its lead program in peanut-allergic toddlers and children. The company’s Viaskin patch platform, regulatory interactions, and late-stage clinical trials form the core of its business profile as a clinical-stage biopharmaceutical issuer listed on Euronext Paris and the Nasdaq Capital Market.